Biotech Values

[DewDiligence]

GLYC reverse-merges with—(private)—Crescent Biopharma:

https://finance.yahoo.com/news/glycomimetics-enters-acquisition-agreement-crescent-110000080.html

Under the terms of the acquisition agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company.

…Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors.

LOL re the 3.1% figure.